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Background: In Ethiopia, the general population is vulnerable to unpredictable epidemics of Plasmodium
falciparum malaria. However, there is little information on the anti-malaria immune profile of the population in the
endemic regions of the country.
Methods: The study was designed to investigate the nature of humoral immune response to malaria in two ethnic
groups in two endemic localities: Shewa Robit in north, and Boditi in south Ethiopia which are characterized by
varying levels of malaria transmission and altitude. In a cross-sectional study, the study participants were diagnosed
for malaria infection microscopically and by the rapid diagnostic test (RDT). Sera were tested by using
enzyme-linked immunosorbent assay (ELISA) for total immunoglobulin (Ig) G against P. falciparum blood-stage
vaccine candidate GMZ2 and its subunits (Glutamate-rich protein (GLURP-R0), merozoite surface protein 3 (MSP3);
as well as IgG subclasses against GLURP-R0 and MSP3.
Results: Whereas 23(8.6%) blood smear-positive cases for P. falciparum were detected in Boditi, all Shewa Robit
study participants had no detectable P. falciparum infection. In both localities, total IgG prevalence and levels to
GMZ2 were significantly higher than the response to the component domains indicating the strong recognition of
GMZ2 by antibodies acquired through natural exposure. Total IgG and subclass prevalence and levels were higher
in Shewa Robit than Boditi, suggesting difference in the intensity of malaria transmission in the two localities and/
or genetic differences between the two populations in their response to the antigens. In both study sites, IgG
subclass levels to GLURP-R0 were significantly higher than that to MSP3 for all corresponding subclasses in most
individuals, indicating the higher relative antigenicity and probably protective potential of GLURP-R0 compared to
MSP3. Against both GLURP-R0 and MSP3, the ratio of cytophilic to noncytophilic antibodies was >1 in the majority
of the study participants, in both study sites, suggesting the induction of protective (cytophilic) antibodies against
the two antigens. Analysis of age-related pattern in antibody levels against the antigens showed a positive
association with increasing age.
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Conclusions: P. falciparum GLURP-R0 and MSP3 separately as well as in a fused form in GMZ2 are readily
recognized by the sera of the study populations. The significantly higher antibody prevalence and level detected
against GMZ2 compared to either of its subunits separately, in naturally exposed populations, suggests the
synergistic effect of GLURP-R0 and MSP3 and that GMZ2 could be a more relevant blood-stage malaria vaccine
candidate than the individual components. Detection of high-level antibody responses in non-febrile,
smear-negative individuals may possibly be an indication of a low-grade, asymptomatic sub-microscopic infection
in the induction and maintenance of high-level malaria immunity.
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Globally, over 225 million malaria cases and 781,000
deaths occur annually [1]. Plasmodium falciparum is the
most widely distributed and deadly species. Drug resist-
ance of the parasite and insecticide resistance of the vec-
tor prove the fight against the disease is challenging. An
effective malaria vaccine would be integrated into exist-
ing control strategies and make malaria elimination/
eradication plans more feasible. Various malaria candi-
date vaccines are at different clinical trial levels; until now
only one of them, the RTS,S vaccine candidate, completed
Phase III [2]. A highly effective malaria vaccine is ex-
pected to be a combined multi-stage, multi-component
and as such a blood-stage component must be included.
But little is understood pertaining to the immune corre-
lates of protection and the appropriate antigens that elicit
the relevant immunological machinery. The concern
increased when two blood-stage vaccines, falciparum mal-
aria protein 1 representing the 42-kDa C-terminal frag-
ment of merozoite surface protein 1 (MSP1) formulated
with AS02 (FMP1/AS02) and apical membrane antigen 1
(AMA1)-C1/Alhydrogel, in Phase IIb trials failed to con-
fer protection despite eliciting high antibody levels [3,4].
Individuals in endemic areas may develop high levels of
antibodies, but these antibodies may not necessarily con-
fer the desired protection. In view of this, it was hypothe-
sized that the absence of protection may be because of an
imbalance in immunoglobulin (Ig) G (IgG) subclass pat-
tern [5]. Blood-stage parasites are mainly attacked by
IgG1 and IgG3 cytophilic, whereas IgG2 and IgG4 noncy-
tophilic may block the protective activity of cytophilic
antibodies [6].
While MSP3 is an erythrocytic-stage protein glutamate-
rich protein (GLURP) is expressed in both pre-
erythrocytic and erythrocytic stages of P. falciparum [7].
A 220-kDa glutamate-rich protein (GLURP) has a rela-
tively conserved N-terminal non-repeat region contain-
ing amino acids 27–500 (fragment R0), a central repeat
region with amino acids 500–705 (fragment R1), and a
C-terminal immunodominant repeat region of amino
acids 705–1178 (fragment R2) [8]. A major B-cell epitope
of the 48-kDa MSP3, which is conserved betweendifferent P. falciparum isolates, is the C-terminal region,
representing amino acids 212–318 [9]. GMZ2 is a
secreted fusion protein produced in Lactococcus lactis
from genetically coupled P. falciparum GLURP-R0 and
MSP3212-380 [10]. Phase I clinical trials of the candidate
vaccine conducted in malaria naïve [11] and naturally
exposed individuals [12] demonstrated the immunogen-
icity, tolerability and safety of GMZ2. Anti-GLURP-R0
and -MSP3 antibody responses may have various forms
of possible interactions – antagonistic, synergistic or no
interaction under natural settings. The objective of this
study was to produce baseline data on antibody
responses to GMZ2 and its component domains in two
epidemic-prone settings in Ethiopia.
Methods
Study sites
The study was carried out in Shewa Robit, a town in
north-central Ethiopia located about 225 km north of
Addis Abeba with geographic coordinates 10°0′36″ N
latitude and 39°54′10.8″ E longitude and Boditi
located in south western Ethiopia, about 370 km away
from the capital having coordinates of 7°2′16.8″ N
latitude and 37°53′16.8″ E longitude (Figure 1). Both
areas receive high rainfall during the main rainy sea-
son (June to September) and are characterized by
markedly unstable seasonal malaria. Most individuals
in the study sites are expected to be exposed to falciparum
malaria at least once in life time. Nationwide, P. falciparum
and P. vivax are the dominant malaria parasites in Ethiopia
accounting for about 60% and 40% of total malaria cases,
respectively. An. arabiensis is main disease vector, while
An. pharoensis, An. funestus and An. nili occasionally
transmit the disease in certain areas of the country [13].
However, no data are currently available pertaining to mal-
aria transmission dynamics, including annual entomo-
logical inoculation rates and prevalence estimates
concerning the two study villages.
Ethical considerations
The study was approved by the Ethics Review Commit-
tee of Department of Biology, Addis Abeba University
Figure 1 Map of Ethiopia showing the location of the two study sites, Boditi and Shewa Robit.
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Federal Ministry of Science and Technology. Informed
consent was obtained from adult participants and par-
ents/legal guardians for children prior to sampling. Mal-
aria smear-positives were treated free of charge as per
the national treatment guideline (P. falciparum: arte-
mether–lumefantrine, P. vivax: chloroquine).Study design, sampling and infection detection
Cross-sectional surveys took place in 2008 (Shewa Robit)
and 2009 (Boditi), both in the dry season when there
was minimum malaria transmission. Five ml of venous
blood was collected from each participant. Malaria RDT
using CareStart™ malaria HRP2/pLDH(Pf/pan) Combo
Cassette Test (Access Bio, Inc) was carried out as per
the manufacturer’s instruction. Thick and thin bloodsmears were prepared and microscopically screened for
Plasmodium infection. Sera were separated and stored
at -20°C until use for immunological assessment. The
flow chart of the study design is shown in Figure 2.Elisa
Total IgG was measured against GMZ2, GLURP-R0 and
MSP3, and IgG subclass levels for GLURP-R0 and MSP3.
All ELISA experiments were performed following a previ-
ously published test protocol [11]. In brief, microtiter
plates (NUNC Maxisorp™, Germany) were coated with
GMZ2 or GLURP at a concentration of 0.5μg/ml and for
MSP3 1μg/ml diluted in phosphate buffered saline (PBS).
The coated plates were washed four times after overnight
incubation at 4°C with a washing buffer (PBS, 0.1% Tween









Antibody against GMZ2, MSP3 and 
GLURP-R0
Figure 2 Study design of antibody analysis against P.
falciparum blood-stage vaccine candidate antigens in Boditi
and Shewa Robit.
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and incubated in a room temperature for 1 h. Optimum
dilutions (1:400 for total IgG and 1:100 for IgG subclasses)
in dilution buffer (PBS, 1% non-fat milk, 0.1% T-20) were
selected prior to the test procedure. Sera were loaded and
the plates were incubated for 2 h in a room temperature
on a shaker. After washing horseradish peroxidase (HRP)-
conjugated goat anti-human IgG (Caltag, USA), diluted
1:3000 in dilution buffer, was added and incubated for 1 h
to detect malaria-specific IgG. After washing 3,3',5,5'-tet-
ramethylbenzidine (TMB-ONE) (KEM EN TEC, Belgium)
was loaded as a substrate for the HRP and incubated in
dark and the reaction stopped by 0.2M H2SO4 (32%,
Merck, Germany) after 20 min. Optical density (OD) was
determined at 450 nm (reference 620 nm) by plate reader
(Asys Expert 96, Type G018065). For IgG subclass analysis
one additional step of incubation was carried out with
HRP-conjugated goat anti-mouse IgG (1:3,000) (Invitrogen,
UK) after capturing the subclasses with mouse anti-human
monoclonal IgG1 (1:3,000) or IgG3 (Skybio, UK), IgG2
(1:5,000) (Sigma, Germany) and IgG4 (1:3,000) (Caltag,
USA). Positive reference serum from Gabonese donors
(Lambaréné) and negative control sera from malaria naïve
German donors were utilized for assay standardization. The
cut-off threshold was determined as the mean plus three
standard deviations (SD) from negative-control sera.Data analysis
The data was double entered into separate Microsoft
Excel spreadsheets and checked for overall correctness
and normality. As mean antibody levels were not normally
distributed, nonparametric tests were used for analyses.
Fisher’s exact test was used to test the significance be-
tween differences in antibody positivity rates for the anti-
gens within and between the two study sites as well as
between age groups, slide-positives and –negatives and
between IgG subclasses. To test the difference in OD
levels between more than two groups the Kruskal-Wallis
test was used. Differences between median OD values for
each antigen between two groups (pairwise) were analyzed
by Mann–Whitney U (Wilcoxon rank-sum) test. Multiple
comparisons were used to assess between which particular
age groups (for more than two age groups) the significant
differences existed. Spearman rank correlation was used
to test the correlation between antibody level to each anti-
gen and the age-related pattern of antibody level. Age-
stratified analysis was followed for comparisons between
the two study sites. Analysis was done using SPSS version
17.0 for Windows (SPSS Inc, Chicago, IL, USA). Two-




Some 228 serum samples were collected from participants
in Shewa Robit. The mean age was 28 years and there
were no individuals below five years of age (range 5–80
years). All participants were asymptomatic and had no
microscopically or RDT detectable Plasmodium infection
at the time of sampling. A total of 265 serum samples was
collected from residents of Boditi with mean age of 23
years. The highest age was 80 and the lowest was one year.
Table 1 shows demographic characteristics of the studied
populations. Some 44 individuals were febrile (axillary
temperature ≥37.5°C). Eleven (25%) among febrile group
were smear-positive for P. falciparum. Twelve asymptom-
atic infections were detected making the total number
of positives 23(8.6%). Only one P. vivax infection was
detected by microscope.
Antibody prevalence and level
Antibody levels to GMZ2, GLURP-R0 and MSP3 were
at detectable level in most individuals in both sites
(Table 2). Positivity rates and levels to GMZ2 were sig-
nificantly higher than that to MSP3 and GLURP-R0 (p <
0.001). Anti-GLURP-R0 total IgG positivity rate was
higher than those to MSP3 in Boditi and the reverse was
observed in Shewa Robit but the differences were not
significant in both cases. Total IgG positivity rates were
higher in Shewa Robit than Boditi for all the three anti-
gens though all the differences were not significant.
Table 1 Demographic characteristics of study participants from Shewa Robit and Boditi in Ethiopia
Study site Age groups Male (n, %) Female (n, %) Total (n, %)
Shewa Robit (N= 228) 5 -14 7 (3.0) 13 (5.7) 20 (8.7)
> 14 181 (79.4) 27 (11.8) 208 (91.2)
Boditi (N = 265) 0 - 4 22 (8.3) 22 (8.3) 44 (16.6)
4.1 - 14 51 (19.2) 36(13.6) 87 (32.8)
>14 40 (15.1) 94 (35.5) 134 (50.6)
n = number of volunteers, % = percentage.
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that to MSP3 or GLURP-R0 in both sites (p <0.001).
Total IgG levels to GLURP-R0 were higher than that to
MSP3 but significant difference was observed only for
Shewa Robit (p = 0.012). For all the three antigens
tested, total IgG positivity rates were higher in Shewa
Robit than Boditi though the differences were not sig-
nificant. Total IgG levels were significantly higher for
GMZ2 (p = 0.013) and GLURP-R0 (p = 0.021) in Shewa
Robit than Boditi between age-stratified groups.
There were some inter-individual variations in IgG re-
activity against GLURP-R0 and MSP3 antigens in both
study sites. An individual who showed high response for
one antigen did not necessarily have a high response for
the other. In Boditi, while a high proportion (71.3%) of
serum samples were IgG positive against GMZ2,
GLURP-R0 and MSP3 only 6.8% did not have a detect-
able IgG level against any of the antigens.Antibody responses by age and smear-positivity
For Shewa Robit, the age group over 14 years old had
greater number of positive individuals than those under
14 for GLURP-R0 and MSP3 (Figure 3) though a signifi-
cant difference was not found for all the three antigens.
But the median total IgG levels to the antigens were sig-
nificantly higher for the older age group for all the three
antigens (p < 0.01) (Figure 3).
For Boditi, there was age-related increase in total IgG
prevalence (Figure 4). There was a significant difference be-
tween age groups under four years and those above 14 in
IgG positivity to GMZ2 (p = 0.005), MSP3 (p = 0.015) and
GLURP-R0 (p <0.001). Levels of total IgG also showed anTable 2 Positivity and levels of total IgG to P. falciparum GMZ
from Boditi and Shewa Robit in Ethiopia
Positivity rate (n, %)
Boditi Shewa Robit
(N=265) (N=228)
GMZ2 240 (90.6) 226 (99.6)
GLURP-R0 226 (85.6) 206 (90.4)
MSP3 216 (81.5) 215 (94.3)age-dependent increase with significant differences between
all the three age groups for GMZ2, between under-four
years and above 14, and between 5–14 years and above 14
for MSP3 and GLURP-R0 (p <0.001) (Figure 4). Though
not significant, the prevalence and levels of total IgG to the
different antigens were higher in the smear-negative group
compared to smear-positives for P. falciparum (Table 3).IgG subclass distribution
Positivity rates of IgG1 and IgG3 to GLURP-R0 and all
subclasses to MSP3 were significantly higher in Shewa
Robit than Boditi between age-stratified groups (Table 4).
Similarly, IgG1 (p = 0.023) and IgG2 (p < 0.001) anti-
body levels to MSP3 were significantly higher in Shewa
Robit than Boditi between age-stratified groups. More
samples were positive to GLURP-R0 but not MSP3 for
all subclass antibodies in both sites. Also, antibody levels
were significantly higher for GLURP-R0 than MSP3 for
IgG1, IgG2 and IgG3 (p < 0.001) in both study popula-
tions. Although it may not necessarily reflect the real
antibody concentration level, in terms of OD values in
the majority of the study populations cytophilic sub-
classes were dominant over the noncytophilic ones for
both antigens in both study sites.Discussion
The significantly higher total IgG prevalence and level
detected in both study sites of the present study for
GMZ2 than either of its two component domains indi-
cates the enhanced antigenicity of GMZ2. The findings
suggest that people in endemic areas have high antibody
levels to the GLURP and MSP3 components of GMZ22 and its component vaccine candidate antigens in sera
Level





















































Age group (years) and Antigens 
Total IgG  responders (%) IgG levels (median OD)
≥ ≥ ≥
Figure 3 The positivity and levels of total IgG antibodies to P.
falciparum, GLURP-R0, MSP3 and GMZ2 in subjects of different
ages from Shewa Robit. The bars represent the proportion of total
IgG responders and the broken line with filled circles represent
levels (median OD) of the response.
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the absence of microscopically detectable infection. The
higher total IgG and subclass levels against GLURP-R0
than MSP3 in both study sites indicates the better anti-
genicity of GLURP-R0 compared to MSP3. The findings
are in line with data from pre-clinical and clinical eva-
luations of the GMZ2 vaccine candidate. Pre-clinical
studies in mice [10] and monkeys [14] documented
higher total IgG prevalence and level against GMZ2
compared to GLURP-R0 and MSP3. The same studies
showed that total IgG prevalence and level were signifi-
cantly higher for GLURP-R0 than MSP3.
Initial clinical trials in malaria-naïve [11] and naturally
exposed individuals [12] to assess safety and immuno-
genicity of GMZ2 have shown stronger anti-GMZ2
responses than the responses to its component antigens,






























Total IgG  responders (%)
Figure 4 The positivity and levels of total IgG antibodies to P. falcipa
from Boditi. The bars represent the proportion of total IgG responders and
the responsethan MSP3. Studies that examined anti-GLURP-R0 and
-MSP3 natural responses separately had recorded vary-
ing total IgG prevalence for the two antigens. In one
such report, anti-MSP3 total IgG prevalence was higher
than that for GLURP-R0 in a hyper-endemic area in
Myanmar [15]. Also, a study from Venezuelan Amazon
showed higher total IgG prevalence against GLURP-R0
than MSP3 [16].
The inter-individual variability in antibody response to
a specific antigen observed among the study participants
was also reported from other malaria endemic areas
[17]. In the present study an individual who showed high
response for MSP3 did not have necessarily high re-
sponse for GLURP-R0 suggesting that no predisposing
host factors are responsible for induction of high anti-
bodies; it may be due to different antigen characteristics.
Currently, knowledge on the durability of antibody
responses to P. falciparum vaccine antigens and how they
are maintained remains poorly defined. In this study, in
the context of heavily reduced transmission, strong im-
mune responses were recorded for all of the antigens in
most study participants. This suggests the stability of mal-
aria immunity. The data provided additional evidence in
support of earlier observations that antibodies can last for
years in the absence of significant boost infections [18,19].
After one year, antibody level to GMZ2 remained high
in the first clinical trial in malaria-naïve adults although it
was lower compared to the level on day 84 [11]. In the ab-
sence of boost infection, anti-GMZ2 antibodies in immu-
nized adults and children lasted six to 12 months [12] and
then started waning. When natural MSP3- and GLURP-
R0-specific IgG subclass levels were considered, no major
change in the levels of specific IgG1 against the two anti-
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rum, GLURP-R0, MSP3 and GMZ2 in subjects of different ages
the broken line with filled circles represent levels (median OD) of
Table 3 The positivity and levels of total IgG antibodies against MSP3, GLURP-R0 and GMZ2 in individuals with




n GMZ2 MSP3 GLURP-R0
Positivity Level Positivity Level Positivity Level
No. (%) (Median OD(IQR) No. (%) (Median OD(IQR) No. (%) (Median OD(IQR)
Negative 242 210 (86.7) 0.435(0.35 200 (82.6) 0.216 208 0.272
0.49) (0.17-0.24) (85.9) (0.21-0.31)
Positive 23 18 (78.2) 0.236(0.19-0.242) 16 (69.5) 0.164 (0.14-0.17) 18 0.186
(78.2) (0.15-0.21)
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some individuals was associated with IgG3 to GLURP-R0
at one time point and IgG3 to MSP3 after five years sug-
gesting changes between individuals in their response to
the antigens and the dynamics (or complementing effect)
of responses to these antigens over time.
The present study suggests that both antigens,
GLURP-R0 and MSP3, are important for the induction
of protective antibodies against malaria from natural
infections providing additional rational for combining
the two antigens in a hybrid vaccine formulation. Thus
GMZ2 has high potential as a candidate vaccine com-
pared to either GLURP-R0 or MSP3 candidate vaccine
antigens. However, it remains unclear whether the
GMZ2 vaccines would be effective in the heterogeneous
epidemiological settings of Ethiopia as there is evidence
that vaccine-induced antibodies may not be as potent as
those naturally acquired [20]. But the induction of func-
tional antibodies, cytophilic subclasses, following natural
exposure signals that the GMZ2 vaccine would likely be
effective at least through boosting the pre-existing anti-
bodies. The role of challenge infections in boosting vac-
cine stimulated-antibodies for parasitaemia control was
noticed in pre-clinical study in monkeys [14]. Further-
more, there is evidence from Phase I clinical trial inTable 4 The positivity and levels of IgG subclasses to P. falcip




(n, %) (Median OD (IQR)
Boditi Shewa Robit Boditi Shewa Ro
IgG1 171 192 0.302 0.337
(64.5) (84.2) (0.26-0.32) (0.28-0.3
IgG2 203 178 0.246 0.324
(76.6) (78.1) (0.21 0.28) (0.25-0.3
IgG3 147 171 0.135 0.197
(55.5) (75.0) (0.15-0.14) (0.16-0.2
IgG4 73 72 0.018 0.067
(27.5) (31.5) (0.014-0.019) (0.01-0.0naturally exposed adults that the GMZ2 vaccine boosted
pre-existing natural immunity [12]. In some studies
anti-GLURP antibodies were associated with protection
[21], in others not [22]. The association of anti-
body levels to MSP3 with protection has also been
described [23].
The overall dominance of cytophilic IgG subclasses over
the noncytophilic shows the functionality of GLURP-R0-
specific IgG subclasses explaining the ‘better protected’
status of Shewa Robit participants who were asymptom-
atic and microscopy negative. The dominance of MSP3-
specific IgG1 and IgG3 isotypes in Boditi sera goes in
agreement with studies from other settings [21,24]. In
both study sites, IgG subclass antibody level to GLURP-
R0 was significantly higher than that to MSP3 for all cor-
responding subclasses characterized in most individuals
indicating the increased relative antigenicity and protect-
ive potential of GLURP-R0 compared to MSP3.
Factors that control the preferential induction of polar-
ized subclass responses are not well understood in vivo.
Cytokines and B cell activators are involved in inducing Ig
class switching in a model system [25]. It was suggested
that some bacterial antigens are known to induce IgG2 ex-
pression [26] and allergens or helminths stimulate IgG4
and IgE induction [27]. Further, polysaccharides such asarum GLURP-R0 and MSP3 in the sera of residents from
MSP3
Positivity rate Level
(n, %) (Median OD (IQR)
bit Boditi Shewa Robit Boditi Shewa Robit
146 209 0.140 0.230
8) (55.1) (91.7) (0.13-0.18) (0.19-0.25)
89 213 0.055 0.279
6) (33.6) (93.4) (0.03-0.09) (0.21-0.31)
108 146 0.096 0.107
1) (40.8) (64.0) (0.04-0.12) (0.09-0.12)
32 74 0.026 0.088
9) (12.1) (32.4) (0.0.01-0.04) (0.05-0.11)
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elevation [28] especially in response to other parasitic dis-
eases like schistosomiasis [29]. Malaria-specific subclass
pattern and relative proportions may differ from popula-
tion to population depending on various factors such as
level of malaria transmission, human genetics and age,
and type of antigen epitope involved [30].
The age-related increase of antibody levels observed
for the antigens in Shewa Robit is in agreement with
other studies [22,31,32]. Although not significant, anti-
body levels to the antigens in the study were higher in
smear-negative group for P. falciparum infection in Bod-
iti sera. This suggests that smear-negative individuals
were relatively protected due to their high antibody levels.
The prevalence of IgG to MSP2 serogroup antigens in a
seasonal transmission area correlated positively with pres-
ence of parasitaemia at the time of sampling [33]. Such
reports may suggest the influence of recent boost infec-
tions that resulted in relatively elevated antibody responses
in one hand and the lower protective efficacy of the anti-
bodies in parasite control on the other. Nonetheless, in
another study, no relationship was observed between anti-
body responses to GLURP-R0 and GLURP-R2 and pres-
ence or absence of P. falciparum in blood and the level of
parasitaemia [34].
The significantly lower falciparum-specific antibody
level noticed in Boditi than Shewa Robit may be due to
genetic differences between the two population groups,
parasite strain variation in the localities, or level of malaria
transmission. Boditi is a highland fringe at an altitude of
2,059 m above sea level (masl). The seasonality of malaria
in highlands is more pronounced with characteristic lower
immunity compared to warm hotbeds. A classical sero-
logical survey conducted in Ethiopian highlands indicated
that high P. falciparum-specific responses were obtained
for people living at elevations of 1,828 masl and less com-
pared to those at 1,920 or above [35]. Treatment-seeking
behaviour and access to prompt effective treatment
schemes, possession and appropriate usage of insecticide-
treated bed net (ITN), vicinity to mosquito breeding sites,
regularity in indoor residual spray (IRS); and the overall
variations of control methods may account for heterogen-
eity in exposure to infective mosquito bites, making the
level of boost infections more infrequent thereby possibly
contributing towards relatively lower antibody levels in
Boditi study participants. In Shewa Robit (at an elevation
of 1,380 masl) an irrigated tobacco farmland created ideal
pools of mosquito breeding sites. This can be a potential
source of submicroscopic, subpatent infections that main-
tained higher immunity compared to Boditi. The Shewa
Robit study participants who had stronger functional anti-
bodies were asymptomatic and had no microscopically de-
tectable infection suggesting that they were relatively
better protected compared to the Boditi.Conclusions
Detection of high antibody prevalence and level in smear-
negative individuals suggests that people in seasonal mal-
aria transmission areas of Ethiopia acquire and maintain
immune responses to P. falciparum blood-stage antigens
in the absence of microscopically detectable infection.
Higher antibody prevalence and level detected against
GMZ2, compared to its subunits individually, suggests
that this antigen could be a more relevant blood-stage
malaria vaccine candidate. Though a few sera did not
show reactivity to GLURP-R0 and MSP3 in both study
sites, most were positive for all IgG1, IgG2 and IgG3 sub-
classes suggesting that the antigens are readily recognized
in the populations. The ratio of cytophilic to noncytophilic
antibodies against GMZ2 subunits was >1 in the majority
of the study population in both study sites implying the
stimulation of functional IgG subclasses. The highest anti-
body prevalence and level were among adults and varied
between antigens.
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